EGFR and non-small cell lung carcinoma: A clear example of the effectiveness of next-generation KIs was the accelerated FDA approval of osimertinib, a third-generation endothelial growth factor receptor (EGFR) inhibitor, for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).